Graeme Eisenhofer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6511966/publications.pdf

Version: 2024-02-01

494 papers 32,470 citations

91 h-index 159

514 all docs

514 docs citations

514 times ranked

17958 citing authors

g-index

#	Article	IF	CITATIONS
1	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1915-1942.	3.6	2,031
2	Phaeochromocytoma. Lancet, The, 2005, 366, 665-675.	13.7	1,462
3	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	7.4	994
4	Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. Pharmacological Reviews, 2004, 56, 331-349.	16.0	849
5	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 92-102.	2.8	581
6	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	3.9	512
7	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2656-2666.	3.6	447
8	Cardiac Sympathetic Nerve Function in Congestive Heart Failure. Circulation, 1996, 93, 1667-1676.	1.6	376
9	Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4757-4767.	3.6	361
10	Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 800-811.	2.5	355
11	Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel–Lindau Disease and Multiple Endocrine Neoplasia Type 2. New England Journal of Medicine, 1999, 340, 1872-1879.	27.0	335
12	Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. Journal of Clinical Oncology, 2007, 25, 2262-2269.	1.6	316
13	Sympathetic Cardioneuropathy in Dysautonomias. New England Journal of Medicine, 1997, 336, 696-702.	27.0	309
14	Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 2012, 48, 1739-1749.	2.8	304
15	Substantial Production of Dopamine in the Human Gastrointestinal Tract. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3864-3871.	3.6	301
16	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	3.1	299
17	High Frequency of <i>SDHB </i> Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4505-4509.	3.6	299
18	The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines., 2001, 91, 35-62.		292

#	Article	IF	CITATIONS
19	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	3.2	282
20	<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
21	Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans Journal of Physiology, 1992, 453, 45-58.	2.9	265
22	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	3.6	262
23	Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with <i>Succinate Dehydrogenase Subunit B</i> Associated Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 779-786.	3.6	262
24	Increased Cardiac Adrenergic Drive Precedes Generalized Sympathetic Activation in Human Heart Failure. Circulation, 1997, 95, 169-175.	1.6	255
25	Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography. Journal of the National Cancer Institute, 2012, 104, 700-708.	6.3	240
26	Superiority of 6-[18F]-Fluorodopamine Positron Emission TomographyVersus[131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4083-4087.	3.6	237
27	Adrenomedullary Dysplasia and Hypofunction in Patients with Classic 21-Hydroxylase Deficiency. New England Journal of Medicine, 2000, 343, 1362-1368.	27.0	229
28	Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans Journal of Clinical Investigation, 1988, 81, 213-220.	8.2	229
29	Cardiovascular manifestations of phaeochromocytoma. Journal of Hypertension, 2011, 29, 2049-2060.	0.5	224
30	Plasma Metanephrines in the Diagnosis of Pheochromocytoma. Annals of Internal Medicine, 1995, 123, 101.	3.9	222
31	Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol- <i>O</i> -Methyltransferase Within Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2175-2185.	3. 6	219
32	6-[¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension, 2001, 38, 6-8.	2.7	215
33	Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1994, 653, 131-138.	1.7	213
34	Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2068-2075.	3.6	213
35	Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1476-1490.	1.2	209
36	Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake Circulation, 1993, 88, 136-145.	1.6	197

3

#	Article	IF	CITATIONS
37	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.5	190
38	Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel–Lindau syndrome. Endocrine-Related Cancer, 2004, 11, 897-911.	3.1	184
39	Current Treatment of Malignant Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1217-1225.	3.6	180
40	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744.	3.2	177
41	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5. 5	176
42	Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to <i>SDHB</i> Mutations. Journal of Clinical Oncology, 2011, 29, 4137-4142.	1.6	170
43	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	3.1	169
44	Haploinsufficiency of $\langle i \rangle$ steroidogenic factor- $1 \langle i \rangle$ in mice disrupts adrenal development leading to an impaired stress response. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14488-14493.	7.1	167
45	Increased Sympathetic Nerve Activity in Renovascular Hypertension. Circulation, 1999, 99, 2537-2542.	1.6	163
46	Laboratory Evaluation of Pheochromocytoma and Paraganglioma. Clinical Chemistry, 2014, 60, 1486-1499.	3.2	161
47	In vivo measurement of neuronal uptake of norepinephrine in the human heart Circulation, 1988, 78, 41-48.	1.6	157
48	Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Reviews in Endocrine and Metabolic Disorders, 2001, 2, 297-311.	5.7	156
49	Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. European Heart Journal, 2005, 26, 906-913.	2.2	150
50	Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography. Endocrine Reviews, 2004, 25, 568-580.	20.1	145
51	Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene. Journal of the National Cancer Institute, 2015, 107, .	6.3	143
52	Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes Journal of Clinical Investigation, 1996, 97, 1010-1019.	8.2	139
53	Children with Classic Congenital Adrenal Hyperplasia Have Elevated Serum Leptin Concentrations and Insulin Resistance: Potential Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2114-2120.	3.6	136
54	Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. American Journal of Cardiology, 1995, 76, 125-130.	1.6	131

#	Article	IF	CITATIONS
55	Dietary Influences on Plasma and Urinary Metanephrines: Implications for Diagnosis of Catecholamine-Producing Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2841-2849.	3 . 6	131
56	An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 75-84.	2.5	129
57	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	11.4	129
58	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	2.7	127
59	Personalized Management of Pheochromocytoma and Paraganglioma. Endocrine Reviews, 2022, 43, 199-239.	20.1	127
60	Mass Spectrometry–Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	3.2	123
61	Adverse Drug Reactions in Patients with Phaeochromocytoma. Drug Safety, 2007, 30, 1031-1062.	3.2	122
62	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 2018, 64, 1646-1656.	3.2	121
63	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1122-1132.	3 . 6	120
64	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers, 2019, 11, 1505.	3.7	120
65	Catecholamine Synthesis is Mediated by Tyrosinase in the Absence of Tyrosine Hydroxylase. Journal of Neuroscience, 1999, 19, 3519-3526.	3 . 6	119
66	Simultaneous determination of plasma noradrenaline and adrenaline kinetics. Naunyn-Schmiedeberg's Archives of Pharmacology, 1990, 341, 192-9.	3.0	118
67	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clinica Chimica Acta, 2017, 470, 115-124.	1.1	116
68	Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus?. Annals of the New York Academy of Sciences, 2006, 1073, 332-347.	3.8	115
69	Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 3009-3017.	3 . 6	115
70	Positron emission tomographic imaging of cardiac sympathetic innervation and function Circulation, 1990, 81, 1606-1621.	1.6	114
71	Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine Circulation, 1992, 85, 1775-1785.	1.6	114
72	Update on Modern Management of Pheochromocytoma and Paraganglioma. Endocrinology and Metabolism, 2017, 32, 152.	3.0	113

#	Article	IF	CITATIONS
73	A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10377-10382.	7.1	112
74	Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the <i>Succinate Dehydrogenase Subunit B </i> Gene. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4826-4832.	3.6	111
75	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	3.6	111
76	Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. Clinical Chemistry, 2007, 53, 352-354.	3.2	110
77	Positron emission tomographic imaging of cardiac sympathetic Innervation using 6-[18 F]Fluorodopamine: Initial findings in humans. Journal of the American College of Cardiology, 1993, 22, 1961-1971.	2.8	106
78	Plasma Metadrenalines: Do they Provide Useful Information about Sympatho-Adrenal Function and Catecholamine Metabolism?. Clinical Science, 1995, 88, 533-542.	4.3	105
79	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1955-1960.	3.6	104
80	Update on pediatric pheochromocytoma. Pediatric Nephrology, 2009, 24, 943-950.	1.7	102
81	Increased norepinephrine spillover into the jugular veins in essential hypertension Hypertension, 1992, 19, 62-69.	2.7	101
82	The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma. Journal of Nuclear Medicine, 2007, 48, 1599-1606.	5.0	101
83	3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Research, 2000, 868, 191-201.	2.2	99
84	Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 147-155.	1.6	99
85	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 62-69.	1.6	98
86	Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. Journal of the Autonomic Nervous System, 1988, 24, 1-14.	1.9	96
87	Cardiac Sympathetic Dysautonomia in Chronic Orthostatic Intolerance Syndromes. Circulation, 2002, 106, 2358-2365.	1.6	96
88	Mesenteric Organ Production, Hepatic Metabolism, and Renal Elimination of Norepinephrine and Its Metabolites in Humans. Journal of Neurochemistry, 1996, 66, 1565-1573.	3.9	96
89	Biochemical diagnosis of phaeochromocytoma using plasmaâ€free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clinical Endocrinology, 2014, 80, 478-486.	2.4	96
90	Sources and Physiological Significance of Plasma Dopamine Sulfate. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2523-2531.	3.6	95

#	Article	IF	CITATIONS
91	Diagnostic Tests and Biomarkers for Pheochromocytoma and Extra-adrenal Paraganglioma: From Routine Laboratory Methods to Disease Stratification. Endocrine Pathology, 2012, 23, 4-14.	9.0	95
92	Current Progress and Future Challenges in the Biochemical Diagnosis and Treatment of Pheochromocytomas and Paragangliomas. Hormone and Metabolic Research, 2008, 40, 329-337.	1.5	94
93	Direct determination of homovanillic acid release from the human brain, and indicator of central dopaminergic activity. Life Sciences, 1991, 49, 1061-1072.	4.3	93
94	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. International Journal of Cancer, 2005, 114, 139-143.	5.1	92
95	Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 375-384.	3.6	90
96	Neuronal Source of Plasma Dihydroxyphenylalanine. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 856-861.	3.6	88
97	Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy Circulation, 1989, 79, 836-844.	1.6	88
98	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clinical Autonomic Research, 2007, 17, 118-121.	2.5	88
99	Pheochromocytoma as an endocrine emergency. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 121-128.	5 . 7	87
100	Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. European Journal of Endocrinology, 2008, 158, 423-429.	3.7	86
101	Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. Journal of Internal Medicine, 2005, 257, 60-68.	6.0	85
102	Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. Journal of the National Cancer Institute, 2001, 93, 648-649.	6.3	83
103	Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde., 2000, 60, 552-558.		82
104	Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clinica Chimica Acta, 2013, 418, 50-58.	1.1	82
105	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2017, 177, 103-113.	3.7	82
106	Tyrosinase: a developmentally specific major determinant of peripheral dopamine. FASEB Journal, 2003, 17, 1248-1255.	0.5	81
107	Plasma norepinephrine pharmacokinetics during mental challenge Psychosomatic Medicine, 1987, 49, 591-605.	2.0	80
108	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine, 2017, 56, 495-503.	2.3	79

#	Article	IF	CITATIONS
109	The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel–Lindau syndrome. European Journal of Endocrinology, 2007, 156, 483-487.	3.7	78
110	The effects of acute and chronic ingestion of ethanol on the autonomic nervous system. Drug and Alcohol Dependence, 1986, 18, 319-328.	3.2	76
111	Pubertal and Gender-Related Changes in the Sympathoadrenal System in Healthy Children. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5038-5043.	3 . 6	76
112	Pheochromocytoma: Diagnosis and management update. Current Hypertension Reports, 2004, 6, 477-484.	3.5	76
113	Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515.	4.7	76
114	Use of 6â€[¹⁸ F]â€fluorodopamine positron emission tomography (PET) as firstâ€line investigation for the diagnosis and localization of nonâ€metastatic and metastatic phaeochromocytoma (PHEO). Clinical Endocrinology, 2009, 71, 11-17.	2.4	74
115	Impaired adrenal catecholamine system function in mice with deficiency of the ascorbic acid transporter (SVCT2). FASEB Journal, 2003, 17, 1-13.	0.5	73
116	Plasma metanephrines in renal failure. Kidney International, 2005, 67, 668-677.	5. 2	73
117	Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clinical Cancer Research, 2017, 23, 6315-6324.	7.0	73
118	Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	5.1	72
119	Sympathetic discharge to mesenteric organs and the liver. Evidence for substantial mesenteric organ norepinephrine spillover Journal of Clinical Investigation, 1996, 97, 1640-1646.	8.2	70
120	Pheochromocytoma $\hat{a}\in$ update on disease management. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 11-26.	3.2	70
121	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. Clinical Chemistry, 2018, 64, 586-596.	3.2	70
122	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Molecular Psychiatry, 2020, 25, 1611-1617.	7.9	70
123	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics, 2021, 11, 7844-7868.	10.0	70
124	Is There a Third Peripheral Catecholaminergic System? Endogenous Dopamine as an Autocrine/Paracrine Substance Derived from Plasma DOPA and Inactivated by Conjugation. Hypertension Research, 1995, 18, S93-S99.	2.7	69
125	The Importance of Adrenocortical Glucocorticoids for Adrenomedullary and Physiological Response to Stress: A Study in Isolated Glucocorticoid Deficiency. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5920-5924.	3 . 6	69
126	New Advances in the Biochemical Diagnosis of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 29-40.	3.8	68

#	Article	IF	CITATIONS
127	Biochemical Diagnosis of Pheochromocytomaâ€"Is it Time to Switch to Plasma-Free Metanephrines?. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 550-552.	3.6	66
128	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1223-E1233.	3.5	66
129	Emergencies Caused by Pheochromocytoma, Neuroblastoma, or Ganglioneuroma. Endocrinology and Metabolism Clinics of North America, 2006, 35, 699-724.	3.2	65
130	1,111 Patients with Adrenal Incidentalomas Observed at a Single Endocrinological Center: Incidence of Chromaffin Tumors. Annals of the New York Academy of Sciences, 2006, 1073, 38-46.	3.8	65
131	Plasma Metanephrine for Assessing the Selectivity of Adrenal Venous Sampling. Hypertension, 2013, 62, 1152-1157.	2.7	65
132	Urinary excretion of dihydroxyphenylalanine and dopamine during alterations of dietary salt intake in humans. Clinical Science, 1989, 76, 517-522.	4.3	64
133	Stress Dose of Hydrocortisone Is Not Beneficial in Patients with Classic Congenital Adrenal Hyperplasia Undergoing Short-Term, High-Intensity Exercise. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3679-3684.	3.6	64
134	Patients with Classic Congenital Adrenal Hyperplasia Have Decreased Epinephrine Reserve and Defective Glucose Elevation in Response to High-Intensity Exercise. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 591-597.	3.6	64
135	Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Experimental Cell Research, 2009, 315, 2673-2682.	2.6	64
136	Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal re-uptake in the sympathetic nervous system in vivo. Clinical Science, 1989, 76, 171-182.	4.3	63
137	Succinate-to-Fumarate Ratio as a New Metabolic Marker to Detect the Presence of SDHB/D-related Paraganglioma: Initial Experimental and Ex Vivo Findings. Endocrinology, 2014, 155, 27-32.	2.8	63
138	Adipocyte-Specific Hypoxia-Inducible Factor $2\hat{l}_{\pm}$ Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation. Molecular and Cellular Biology, 2016, 36, 376-393.	2.3	63
139	Mutations in MDH2, Encoding a Krebs Cycle Enzyme, Cause Early-Onset Severe Encephalopathy. American Journal of Human Genetics, 2017, 100, 151-159.	6.2	63
140	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
141	Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. Clinical Autonomic Research, 1991, 1, 187-194.	2.5	61
142	Pheochromocytoma: Rediscovery as a catecholamine-metabolizing tumor. Endocrine Pathology, 2003, 14, 193-212.	9.0	61
143	Diagnostic Localization of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 170-176.	3.8	60
144	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocrine-Related Cancer, 2008, 15, 311-323.	3.1	60

#	Article	IF	Citations
145	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	2.4	60
146	Adrenomedullary Function May Predict Phenotype and Genotype in Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3031-3037.	3.6	59
147	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556.	3.8	59
148	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 2019, 181, 409-420.	3.7	58
149	Effects of ethanol on plasma catecholamines and norepinephrine clearance. Clinical Pharmacology and Therapeutics, 1983, 34, 143-147.	4.7	57
150	Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology, 2005, 153, 551-563.	3.7	57
151	Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol-O-Methyltransferase Within Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2175-2185.	3.6	57
152	Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. Neuropsychopharmacology, 1999, 20, 29-34.	5.4	56
153	Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients. Journal of the Endocrine Society, 2020, 4, bvaa102.	0.2	56
154	Neuronal reuptake of norepinephrine and production of dihydroxyphenylglycol by cardiac sympathetic nerves in the anesthetized dog Circulation, 1991, 84, 1354-1363.	1.6	54
155	Biochemical Diagnosis of Pheochromocytoma. , 2003, 31, 76-106.		54
156	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	10.0	54
157	Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2013, 19, 3787-3795.	7.0	53
158	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
159	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clinical Cancer Research, 2019, 25, 3152-3163.	7.0	53
160	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	5.9	53
161	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. Archives of Pathology and Laboratory Medicine, 2014, 138, 182-188.	2.5	52
162	A "Pheo―Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646.	3.6	51

#	Article	IF	CITATIONS
163	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	2.7	51
164	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. American Journal of Human Genetics, 2019, 104, 651-664.	6.2	51
165	Deletion of tyrosine hydroxylase gene reveals functional interdependence of adrenocortical and chromaffin cell system in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14742-14747.	7.1	50
166	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clinica Chimica Acta, 2019, 490, 46-54.	1.1	50
167	Plasma 3, 4-Dihydroxyphenylalanine (Dopa) and Catecholamines in Neuroblastoma or Pheochromocytoma. Annals of Internal Medicine, 1986, 105, 887.	3.9	49
168	Regional homovanillic acid production in humans. Life Sciences, 1993, 53, 63-75.	4.3	49
169	Leaky Catecholamine Stores: Undue Waste or a Stress Response Coping Mechanism?. Annals of the New York Academy of Sciences, 2004, 1018, 224-230.	3.8	49
170	Dopamine Produced by the Stomach May Act as a Paracrine/ Autocrine Hormone in the Rat. Neuroendocrinology, 1998, 67, 336-348.	2.5	48
171	Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocrine-Related Cancer, 2005, 12, 263-272.	3.1	47
172	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	3.7	47
173	Free or Total Metanephrines for Diagnosis of Pheochromocytoma: What Is the Difference?. Clinical Chemistry, 2001, 47, 988-989.	3.2	47
174	Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. Journal of the Autonomic Nervous System, 1991, 34, 17-35.	1.9	46
175	Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clinical Biochemist Reviews, 2017, 38, 69-100.	3.3	46
176	Plasma Dihydroxyphenylalanine and Total Body and Regional Noradrenergic Activity in Humans. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 247-255.	3.6	45
177	Mortality Associated with Phaeochromocytoma. Hormone and Metabolic Research, 2013, 45, 154-158.	1.5	45
178	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
179	Increased cardiac sympathetic drive in renovascular hypertension. Journal of Hypertension, 2002, 20, 1181-1187.	0.5	44
180	Mutations associated with succinate dehydrogenase <scp>d</scp> â€related malignant paragangliomas. Clinical Endocrinology, 2008, 68, 561-566.	2.4	44

#	Article	IF	CITATIONS
181	Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15879-15884.	7.1	44
182	Differences in the Neuronal Removal of Circulating Epinephrine and Norepinephrine. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1710-1720.	3.6	43
183	PRKACA Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3010-3017.	3.6	43
184	Source and Physiological Significance of Plasma 3,4-Dihydroxyphenylalanine in the Rat. Journal of Neurochemistry, 1988, 51, 1204-1213.	3.9	42
185	Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. Naunyn-Schmiedeberg's Archives of Pharmacology, 1992, 345, 160-171.	3.0	42
186	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. Journal of Hypertension, 2007, 25, 2286-2295.	0.5	42
187	Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocrine-Related Cancer, 2009, 16, 291-299.	3.1	42
188	Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 359-363.	3.6	42
189	Pheochromocytoma and Pregnancy. Endocrinology and Metabolism Clinics of North America, 2019, 48, 605-617.	3.2	42
190	SYMPATHETIC AND RENIN-ANGIOTENSIN ACTIVATION DURING GRADED HYPOVOLEMIA IN PIGS. Shock, 1997, 8, 378-384.	2.1	41
191	Changes in morphology and function of adrenal cortex in mice fed a high-fat diet. International Journal of Obesity, 2015, 39, 321-330.	3.4	41
192	Diagnosis and Localization of Pheochromocytoma. Hypertension, 2004, 43, 907-910.	2.7	40
193	Patients with Classic Congenital Adrenal Hyperplasia Have Decreased Epinephrine Reserve and Defective Glycemic Control during Prolonged Moderate-Intensity Exercise. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3019-3024.	3.6	40
194	Clinical utility of chromogranin A in <i><scp>SDH</scp>xâ€</i> related paragangliomas. European Journal of Clinical Investigation, 2014, 44, 365-371.	3.4	40
195	A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646.	3.6	40
196	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. Journal of the Autonomic Nervous System, 1994, 50, 93-107.	1.9	39
197	The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now. Endocrine Pathology, 2014, 25, 49-58.	9.0	39
198	Anti-Tumorigenic and Anti-Metastatic Activity of the Sponge-Derived Marine Drugs Aeroplysinin-1 and Isofistularin-3 against Pheochromocytoma In Vitro. Marine Drugs, 2018, 16, 172.	4.6	39

#	Article	IF	CITATIONS
199	Vasopressin Concentrations during Alcohol Withdrawal. Addiction, 1985, 80, 195-199.	3.3	38
200	Multimodal Somatostatin Receptor Theranostics Using [⁶⁴ Cu]Cu-/[¹⁷⁷ Lu]Lu-DOTA-(Tyr ³)octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics, 2016, 6, 650-665.	10.0	38
201	Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. Journal of Hypertension, 1991, 9, 417-423.	0.5	37
202	Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients. Metabolism: Clinical and Experimental, 1999, 48, 543-545.	3.4	37
203	Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. Biomedical Applications, 1999, 729, 347-353.	1.7	36
204	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones, 2009, 8, 111-116.	1.9	36
205	Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 1121.	3.7	36
206	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. American Journal of Medicine, 2013, 126, 174-180.	1.5	35
207	Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. Clinical Endocrinology, 2015, 83, 298-302.	2.4	35
208	Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4331-4340.	3.6	35
209	The role of regulated necrosis in endocrine diseases. Nature Reviews Endocrinology, 2021, 17, 497-510.	9.6	35
210	Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 287-94.	3.0	34
211	Screening for Pheochromocytomas and Paragangliomas. Current Hypertension Reports, 2012, 14, 130-137.	3.5	34
212	Role of Hypoxia and HIF2 \hat{l}_{\pm} in Development of the Sympathoadrenal Cell Lineage and Chromaffin Cell Tumors with Distinct Catecholamine Phenotypic Features. Advances in Pharmacology, 2013, 68, 285-317.	2.0	34
213	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3295-3307.	3.6	34
214	Endocrine Conditions and COVID-19. Hormone and Metabolic Research, 2020, 52, 471-484.	1.5	34
215	Chromaffin cells: the peripheral brain. Molecular Psychiatry, 2012, 17, 354-358.	7.9	33
216	Genotype-Specific Differences in the Tumor Metabolite Profile of Pheochromocytoma and Paraganglioma Using Untargeted and Targeted Metabolomics. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E214-E222.	3.6	33

#	Article	IF	Citations
217	Attenuated Cardiac Sympathetic Responsiveness During Dynamic Exercise in Patients With Heart Failure. Circulation, 1997, 95, 940-945.	1.6	33
218	HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocrine-Related Cancer, 2020, 27, 625-640.	3.1	33
219	Selegiline in ADHD Adults: Plasma Monoamines and Monoamine Metabolites. Neuropsychopharmacology, 1997, 16, 276-284.	5.4	32
220	Dopamine lesionâ€induced changes in subthalamic nucleus activity are not associated with alterations in firing rate or pattern in layer V neurons of the anterior cingulate cortex in anesthetized rats. European Journal of Neuroscience, 2007, 26, 1925-1939.	2.6	32
221	Subtyping of Patients with Primary Aldosteronism: An Update. Hormone and Metabolic Research, 2017, 49, 922-928.	1.5	32
222	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 353-363.	2.3	32
223	Differentiated Response of the Sympathetic Nervous System to Angiotensin-Converting Enzyme Inhibition in Hypertension. Hypertension, 2000, 36, 543-548.	2.7	31
224	Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells. BMC Cancer, 2012, 12, 576.	2.6	30
225	Is adrenaline released by sympathetic nerves in man?. Clinical Autonomic Research, 1991, 1, 103-108.	2.5	29
226	Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. Journal of the Autonomic Nervous System, 1997, 66, 145-148.	1.9	29
227	Splanchnic circulation and regional sympathetic outflow during peroperative PEEP ventilation in humans. British Journal of Anaesthesia, 1999, 82, 838-842.	3.4	29
228	Chromaffin cell function and structure is impaired in corticotropin-releasing hormone receptor type 1-null mice. Molecular Psychiatry, 2002, 7, 967-974.	7.9	29
229	Principles of Catecholamine Biosynthesis, Metabolism and Release. , 2003, 31, 1-25.		29
230	Pheochromocytoma. Clinical Chemistry, 2013, 59, 466-472.	3.2	29
231	Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy. Clinica Chimica Acta, 2019, 494, 100-105.	1.1	29
232	Neuronal Re-Uptake of Noradrenaline by Sympathetic Nerves in Humans. Clinical Science, 1991, 80, 257-263.	4.3	28
233	Impact of LC-MS/MS on the laboratory diagnosis of catecholamine-producing tumors. TrAC - Trends in Analytical Chemistry, 2016, 84, 106-116.	11.4	28
234	Elevated Steroid Hormone Production in the db/db Mouse Model of Obesity and Type 2 Diabetes. Hormone and Metabolic Research, 2017, 49, 43-49.	1.5	28

#	Article	IF	Citations
235	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	2.5	28
236	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1955-1960.	3.6	28
237	Opposite changes in turnover of noradrenaline and dopamine in the CNS of ethanol-dependent mice. Neuropharmacology, 1990, 29, 37-45.	4.1	27
238	Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1994, 349, 259-69.	3.0	27
239	Hemodynamic, sympathetic and angiotensin II responses to PEEP ventilation before and during administration of isoflurane. Acta Anaesthesiologica Scandinavica, 1997, 41, 41-48.	1.6	27
240	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245.	3.6	27
241	Interference from 3-O-Methyldopa with Ultra–High Performance LC-MS/MS Measurements of Plasma Metanephrines: Chromatographic Separation Remains Important. Clinical Chemistry, 2015, 61, 993-996.	3.2	27
242	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2027-e2036.	3.6	27
243	Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro-Oncology, 2013, 15, 682-690.	1.2	26
244	Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Annals of Clinical Biochemistry, 2014, 51, 38-46.	1.6	26
245	Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells. Molecular Psychiatry, 2015, 20, 941-950.	7.9	26
246	The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. Endocrine-Related Cancer, 2017, 24, 555-564.	3.1	26
247	Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R165-R173.	1.8	25
248	Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines. Current Hypertension Reports, 2002, 4, 250-255.	3.5	25
249	Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor. Endocrine Practice, 2003, 9, 310-314.	2.1	25
250	Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. European Journal of Endocrinology, 2014, 170, 349-357.	3.7	25
251	Analytical differences between the determination of plasma catecholamines by liquid chromatography with electrochemical detection and by radioenzymatic assay. Biomedical Applications, 1986, 377, 328-333.	1.7	24
252	Effects of Risperidone on the Peripheral Noradrenegic System in Patients with Schizophrenia A Comparison with Clozapine and Placebo. Neuropsychopharmacology, 2002, 27, 293-300.	5.4	24

#	Article	IF	CITATIONS
253	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Annals of the New York Academy of Sciences, 2006, 1073, 241-252.	3.8	24
254	Pathophysiology and Diagnosis of Disorders of the Adrenal Medulla: Focus on Pheochromocytoma., 2014, 4, 691-713.		24
255	Closing the GAPP on predicting metastases. Nature Reviews Endocrinology, 2014, 10, 315-316.	9.6	24
256	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
257	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif $2\hat{l}\pm$ in Pheochromocytoma Cells. Cancers, 2019, 11, 594.	3.7	24
258	Effects of ethanol on cardiovascular and catecholamine responses to mental stress. Journal of Psychosomatic Research, 1986, 30, 93-102.	2.6	23
259	Parallel increases in noradrenaline reuptake and release into plasma during activation of the sympathetic nervous system in rabbits. Naunyn-Schmiedeberg's Archives of Pharmacology, 1990, 342, 328-35.	3.0	23
260	Precisely Wrong? Urinary Fractionated Metanephrines and Peer-Based Laboratory Proficiency Testing. Clinical Chemistry, 2005, 51, 472-474.	3.2	23
261	Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET. Journal of Nuclear Medicine, 2007, 48, 1940-1944.	5.0	23
262	Candidate Genes Associated With Malignant Pheochromocytomas by Genome-Wide Expression Profiling. Annals of Surgery, 2009, 250, 983-990.	4.2	23
263	Differentiation of Chromaffin Progenitor Cells to Dopaminergic Neurons. Cell Transplantation, 2012, 21, 2471-2486.	2.5	23
264	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. Cell and Tissue Research, 2018, 374, 473-485.	2.9	23
265	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers, 2019, 11, 809.	3.7	23
266	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers, 2019, 11, 2028.	3.7	23
267	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	4.5	23
268	Aldose reductase, a key enzyme in the oxidative deamination of norepinephrine in rats. Biochemical Pharmacology, 1999, 58, 517-524.	4.4	22
269	Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. Cell and Tissue Research, 2005, 322, 443-453.	2.9	22
270	Sympathetic nerve function. Clinical Autonomic Research, 2005, 15, 264-283.	2.5	22

#	Article	IF	Citations
271	Pheochromocytoma. Annals of the New York Academy of Sciences, 2008, 1148, 462-468.	3.8	22
272	A Transgenic Mouse Model of Pacak–Zhuang Syndrome with An Epas1 Gain-of-Function Mutation. Cancers, 2019, 11, 667.	3.7	22
273	Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases. JCl Insight, 2019, 4, .	5.0	22
274	Effects of ethanol ingestion on alphaâ€adrenoceptorâ€mediated circulatory responses in man British Journal of Clinical Pharmacology, 1984, 18, 581-586.	2.4	21
275	Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats. Neurochemical Research, 1999, 24, 25-32.	3.3	21
276	Adrenal medullary dysfunction as a feature of obesity. International Journal of Obesity, 2017, 41, 714-721.	3.4	21
277	Adrenal cortical and chromaffin stem cells: Is there a common progeny related to stress adaptation?. Molecular and Cellular Endocrinology, 2017, 441, 156-163.	3.2	21
278	Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease?. Molecular Psychiatry, 2019, 24, 2-9.	7.9	21
279	The Incidentally Discovered Adrenal Mass. New England Journal of Medicine, 2007, 356, 2005-2006.	27.0	20
280	Autonomic Nervous System Function in Rheumatoid Arthritis. Cellular and Molecular Neurobiology, 2012, 32, 897-901.	3.3	20
281	Cancer Stem Cells in Pheochromocytoma and Paraganglioma. Frontiers in Endocrinology, 2020, 11, 79.	3.5	20
282	Harmonization of LC-MS/MS Measurements of Plasma Free Normetanephrine, Metanephrine, and 3-Methoxytyramine. Clinical Chemistry, 2021, 67, 1098-1112.	3.2	20
283	Sources and Physiological Significance of Plasma Dopamine Sulfate. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2523-2531.	3.6	20
284	Norepinephrine Spillover in Forearm and Subcutaneous Adipose Tissue before and after Eating. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2815-2819.	3.6	20
285	Increased cardiac production of dihydroxyphenylalanine (DOPA) during sympathetic stimulation in anaesthetized dogs. Neurochemistry International, 1992, 21, 37-44.	3.8	19
286	An assessment of biochemical tests for the diagnosis of pheochromocytoma. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 744-745.	2.8	19
287	Adrenomedullary Function in Patients with Nonclassic Congenital Adrenal Hyperplasia. Hormone and Metabolic Research, 2010, 42, 607-612.	1.5	19
288	Reducing agents induce thrombomodulin shedding in human endothelial cells. Thrombosis Research, 2010, 126, e88-e93.	1.7	19

#	Article	IF	CITATIONS
289	Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. European Journal of Endocrinology, 2018, 178, K1-K9.	3.7	19
290	Optimized Reference Intervals for Plasma Free Metanephrines in Patients With CKD. American Journal of Kidney Diseases, 2018, 72, 907-909.	1.9	19
291	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3812-3820.	3.6	19
292	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. European Journal of Endocrinology, 2019, 181, 647-657.	3.7	19
293	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1181-e1192.	3.6	19
294	Growth Hormone, Vasopressin, Cortisol, and Catecholamine Responses to Insulin Hypoglycemia in Alcoholics. Alcoholism: Clinical and Experimental Research, 1984, 8, 33-36.	2.4	18
295	Left Ventricular Structural and Functional Alterations in Patients With Pheochromocytoma/Paraganglioma Before and After Surgery. JACC: Cardiovascular Imaging, 2020, 13, 2498-2509.	5.3	18
296	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. European Journal of Cancer, 2022, 169, 32-41.	2.8	18
297	Acidic dopamine metabolites are actively extruded from PC12 cells by a novel sulfonylurea-sensitive transporter. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 654-664.	3.0	17
298	Aldose reductase: An aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia. Autonomic Neuroscience: Basic and Clinical, 2002, 96, 131-139.	2.8	17
299	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	3.7	17
300	Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing's syndrome. Gynecological Endocrinology, 2018, 34, 20-24.	1.7	17
301	Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism—a Review. Current Hypertension Reports, 2019, 21, 77.	3.5	17
302	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
303	The longevity gene mIndy (l'm Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms. JCI Insight, 2021, 6, .	5.0	17
304	Plasma levels of catechols during reflexive changes in sympathetic nerve activity. Neurochemical Research, 1989, 14, 523-531.	3.3	16
305	PNMT Transgenic Mice Have an Aggressive Phenotype. Hormone and Metabolic Research, 2005, 37, 159-163.	1.5	16
306	Chromogranin A Expression in Phaeochromocytomas Associated with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Hormone and Metabolic Research, 2007, 39, 876-883.	1.5	16

#	Article	IF	Citations
307	Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine, 2008, 34, 96-100.	2.3	16
308	Involvement of Epigenetic Mechanisms in the Regulation of Secreted Phospholipase A2 Expressions in Jurkat Leukemia Cells. Neoplasia, 2008, 10, 1195-1203.	5.3	16
309	In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma. Endocrinology, 2014, 155, 4149-4156.	2.8	16
310	Time matters – Acute stress response and glucocorticoid sensitivity in early multiple sclerosis. Brain, Behavior, and Immunity, 2014, 41, 82-89.	4.1	16
311	Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576.	5.3	16
312	Noradrenaline reuptake and plasma dihydroxyphenylglycol during sustained changes in sympathetic activity in rabbits. Journal of the Autonomic Nervous System, 1991, 32, 217-231.	1.9	15
313	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. Stress, 1997, 2, 113-122.	1.8	15
314	Tyrosine hydroxylase assay for detection of low levels of enzyme activity in peripheral tissues. Biomedical Applications, 1997, 694, 317-324.	1.7	15
315	Determinants of cardiac tyrosine hydroxylase activity during exercise-induced sympathetic activation in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 274, R626-R634.	1.8	15
316	Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. Hypertension, 2004, 43, 1227-1232.	2.7	15
317	Unexplained Symptomatic Paroxysmal Hypertension in Pseudopheochromocytoma. Annals of the New York Academy of Sciences, 2008, 1148, 469-478.	3.8	15
318	Plasmaâ€free <i>vs</i> deconjugated metanephrines for diagnosis of phaeochromocytoma. Clinical Endocrinology, 2013, 79, 476-483.	2.4	15
319	Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects. Journal of Clinical Psychopharmacology, 2014, 34, 9-16.	1.4	15
320	$HIF1\hat{l}_{\pm}$ is a direct regulator of steroidogenesis in the adrenal gland. Cellular and Molecular Life Sciences, 2021, 78, 3577-3590.	5.4	15
321	The Importance of Adrenocortical Glucocorticoids for Adrenomedullary and Physiological Response to Stress: A Study in Isolated Glucocorticoid Deficiency. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5920-5924.	3.6	15
322	BRAIN WATER DURING ALCOHOL WITHDRAWAL. Lancet, The, 1982, 319, 50.	13.7	14
323	Differential actions of desipramine on sympathoadrenal release of noradrenaline and adrenaline British Journal of Clinical Pharmacology, 1995, 40, 263-265.	2.4	14
324	Cardiorenal epinephrine kinetics: evidence for neuronal release in the human heart. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H2178-H2185.	3.2	14

#	Article	IF	Citations
325	High-Throughput, Automated, and Accurate Biochemical Screening for Pheochromocytoma: Are We There Yet?. Clinical Chemistry, 2007, 53, 1565-1567.	3.2	14
326	Proteomic profiling of von Hippel–Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. Endocrine-Related Cancer, 2007, 14, 463-471.	3.1	14
327	Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel–Lindau syndrome. Journal of Endocrinology, 2007, 193, 225-233.	2.6	14
328	Direct effect of dehydroepiandrosterone sulfate (DHEAS) on PC-12 cell differentiation processes. Molecular and Cellular Endocrinology, 2011, 336, 149-155.	3.2	14
329	Steroid Hormone Production in Patients with Aldosterone Producing Adenomas. Hormone and Metabolic Research, 2015, 47, 967-972.	1.5	14
330	Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats. Endocrinology, 2016, 157, 3844-3855.	2.8	14
331	Biochemical testing for neuroblastoma using plasma free 3â€Oâ€methyldopa, 3â€methoxytyramine, and normetanephrine. Pediatric Blood and Cancer, 2020, 67, e28081.	1.5	14
332	Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome – a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1264-1272.	2.3	14
333	Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. Cancers, 2021, 13, 4758.	3.7	14
334	Clinical Catecholamine Neurochemistry: A Legacy of Julius Axelrod. Cellular and Molecular Neurobiology, 2006, 26, 693-700.	3.3	13
335	Combined Use of 68Ga-DOTATATE and 18F-FDG PET/CT to Localize a Bronchial Carcinoid Associated with Ectopic ACTH Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2207-2208.	3.6	13
336	Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nuclear Medicine and Biology, 2012, 39, 215-226.	0.6	13
337	Adrenomedullary Function May Predict Phenotype and Genotype in Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3031-3037.	3.6	13
338	Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?. European Journal of Endocrinology, 2020, 182, 499-509.	3.7	13
339	Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. Endocrine-Related Cancer, 2020, 27, 403-413.	3.1	13
340	Cardiac Noradrenergic Function One Year Following Cardiac Transplantation. Blood Pressure, 1993, 2, 252-261.	1.5	12
341	Splanchnic and Renal Sympathetic Activity in Relation to Hemodynamics During Isoflurane Administration in Pigs. Anesthesia and Analgesia, 1995, 80, 135-142.	2,2	12
342	Catecholamine Metabolism. Advances in Pharmacology, 1997, , 273-292.	2.0	12

#	Article	IF	CITATIONS
343	Hyperleptinaemia does not correlate with plasma catecholamine levels in chronic heart failure. European Heart Journal, 1999, 20, 1051-1052.	2.2	12
344	Effect of glipizide on dopamine synthesis, release and metabolism in PC12 cells. European Journal of Pharmacology, 2000, 388, 147-154.	3.5	12
345	Diagnostic Imaging of Pheochromocytoma. , 2003, 31, 107-120.		12
346	Risks of hemodynamic instability in pheochromocytoma. Nature Reviews Endocrinology, 2010, 6, 301-302.	9.6	12
347	A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. Nature Reviews Endocrinology, 2011, 7, 749-755.	9.6	12
348	Rapid circulatory clearances and halfâ€lives of plasma free metanephrines. Clinical Endocrinology, 2012, 77, 484-485.	2.4	12
349	Dipping in Ambulatory Blood Pressure Monitoring Correlates With Overnight Urinary Excretion of Catecholamines and Sodium. Journal of Clinical Hypertension, 2016, 18, 921-926.	2.0	12
350	Computational analysis of liquid chromatography-tandem mass spectrometric steroid profiling in NCI H295R cells following angiotensin II, forskolin and abiraterone treatment. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 67-75.	2.5	12
351	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. International Journal of Obesity, 2019, 43, 263-275.	3.4	12
352	Hypoxia-inducible Factor 2α: A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma?. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 282-289.	1.2	12
353	Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis. Neuro-Oncology, 2022, 24, 1509-1523.	1,2	12
354	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	3.1	12
355	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocrine-Related Cancer, 2022, 29, 213-224.	3.1	12
356	Catecholamine Phenotyping: Clues to the Diagnosis, Treatment, and Pathophysiology of Neurogenetic Disorders. Journal of Neurochemistry, 2002, 67, 1781-1790.	3.9	11
357	Expression and shedding of endothelial protein C receptor in prostate cancer cells. Cancer Cell International, 2011, 11, 4.	4.1	11
358	Genetic Screening for von Hippel-Lindau Gene Mutations in Non-syndromic Pheochromocytoma: Low Prevalence and False-positives or Misdiagnosis Indicate a Need for Caution. Hormone and Metabolic Research, 2012, 44, 343-348.	1.5	11
359	Regulation of thrombomodulin expression in prostate cancer cells. Cancer Letters, 2012, 322, 177-184.	7.2	11
360	Supine or Sitting? Economic and other considerations for use of plasma metanephrines for diagnosis of phaeochromocytoma. Clinical Endocrinology, 2015, 82, 463-464.	2.4	11

#	Article	IF	Citations
361	Biochemical Diagnosis of Pheochromocytoma, a Rediscovered Catecholamine-Metabolizing Tumor. Clinical Chemistry, 2018, 64, 1780-1781.	3.2	11
362	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. Metabolism: Clinical and Experimental, 2020, 110, 154297.	3.4	11
363	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocrine Connections, 2018, 7, 1168-1177.	1.9	11
364	Generation and characterization of a mitotane-resistant adrenocortical cell line. Endocrine Connections, 2020, 9, 122-134.	1.9	11
365	Report from the HarmoSter study: impact of calibration on comparability of LC-MS/MS measurement of circulating cortisol, 17OH-progesterone and aldosterone. Clinical Chemistry and Laboratory Medicine, 2022, 60, 726-739.	2.3	11
366	Implications of Plasma Levels of Catechols in the Evaluation of SympathoadrenomeduUary Function. American Journal of Hypertension, 1989, 2, 133S-139S.	2.0	10
367	Differential Effects of Central and Peripheral Desipramine on Sympathoadrenal Function and Heart Rate in Conscious Rabbits. Journal of Cardiovascular Pharmacology, 1991, 17, 519-531.	1.9	10
368	Genetic Deficiencies of Monoamine Oxidase Enzymes: A Key to Understanding the Function of the Enzymes in Humans. Advances in Pharmacology, 1997, 42, 297-301.	2.0	10
369	Dehydroepiandrosterone-sulphate (DHEA-S) promotes neuroendocrine differentiation of chromaffin pheochromocytoma PC12 cells. Molecular and Cellular Endocrinology, 2009, 300, 126-131.	3.2	10
370	Morphology, Biochemistry, and Pathophysiology of MENX-Related Pheochromocytoma Recapitulate the Clinical Features. Endocrinology, 2016, 157, 3157-3166.	2.8	10
371	Preservation of urine free catecholamines and their free O-methylated metabolites with citric acid as an alternative to hydrochloric acid for LC-MS/MS-based analyses. Clinical Chemistry and Laboratory Medicine, 2016, 54, 37-43.	2.3	10
372	Novel methods in adrenal research: a metabolomics approach. Histochemistry and Cell Biology, 2019, 151, 201-216.	1.7	10
373	DISSOCIATION BETWEEN CORTICOTROPHIN AND CATECHOLAMINE RESPONSES TO ISOPRENALINE IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 337-341.	1.9	9
374	Simultaneous determination of endogenous catechols and exogenous 2- and 6-fluorinated catechols in tissue and plasma using liquid chromatography with electrochemical detection. Biomedical Applications, 1988, 431, 156-162.	1.7	9
375	Pharmacologic and Tracer Methods to Study Sympathetic Function in Primary Hypertension. Clinical and Experimental Hypertension, 1989, 11, 173-189.	0.3	9
376	ADRENALINE RELEASE BY THE HUMAN HEART. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 67-70.	1.9	9
377	Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase. Neuropsychopharmacology, 1996, 15, 296-301.	5.4	9
378	Utility of Plasma Free Metanephrines in Diagnosis of Factitious Pheochromocytoma. Endocrine Practice, 2006, 12, 568-571.	2.1	9

#	Article	IF	Citations
379	High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. Cancer Investigation, 2012, 30, 343-363.	1.3	9
380	The Catalytic Subunit \hat{l}^2 of PKA Affects Energy Balance and Catecholaminergic Activity. Journal of the Endocrine Society, 2019, 3, 1062-1078.	0.2	9
381	Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics. Endocrine-Related Cancer, 2021, 28, 65-77.	3.1	9
382	$HIF2\hat{l}\pm$ regulates the synthesis and release of epinephrine in the adrenal medulla. Journal of Molecular Medicine, 2021, 99, 1655-1666.	3.9	9
383	Splanchnic and Renal Sympathetic Activity in Relation to Hemodynamics During Isoflurane Administration in Pigs. Anesthesia and Analgesia, 1995, 80, 135-142.	2.2	8
384	Intracoronary blockade of angiotensinâ€converting enzyme in humans: Interaction with cardiac sympathetic neurotransmission?. Acta Physiologica Scandinavica, 1997, 161, 15-22.	2.2	8
385	Pheochromocytoma and Paraganglioma: Recent Progress and New Vistas for Improved Patient Care. Hormone and Metabolic Research, 2012, 44, 325-327.	1.5	8
386	Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells. Molecular and Cellular Endocrinology, 2013, 371, 189-194.	3.2	8
387	Pheochromocytoma Presenting as Takotsubo-Like Cardiomyopathy Following Delivery. Endocrine Practice, 2014, 20, 233-236.	2.1	8
388	A Defined, Controlled Culture System for Primary Bovine Chromaffin Progenitors Reveals Novel Biomarkers and Modulators. Stem Cells Translational Medicine, 2014, 3, 801-808.	3.3	8
389	Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomas—Case Report. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2321-2326.	3.6	8
390	Beyond a Disease Registry: An Integrated Virtual Environment for Adrenal Cancer Research. Journal of Grid Computing, 2016, 14, 515-532.	3.9	8
391	Steroid Profiling for Adrenocortical Disorders: A Pathway for Omics-Based Diagnostics. Clinical Chemistry, 2017, 63, 1787-1789.	3.2	8
392	Steroid metabolomics: machine learning and multidimensional diagnostics for adrenal cortical tumors, hyperplasias, and related disorders. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 40-49.	1.4	8
393	Fluorescent mouse pheochromocytoma spheroids expressing hypoxia-inducible factor 2 alpha: Morphologic and radiopharmacologic characterization. Journal of Cellular Biotechnology, 2019, 5, 135-151.	0.5	8
394	Phaeochromocytoma â€" advances through science, collaboration and spreading the word. Nature Reviews Endocrinology, 2020, 16, 621-622.	9.6	8
395	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. Clinica Chimica Acta, 2020, 507, 98-103.	1.1	8
396	Adrenal Hormone Interactions and Metabolism: A Single Sample Multi-Omics Approach. Hormone and Metabolic Research, 2021, 53, 326-334.	1.5	8

#	Article	IF	CITATIONS
397	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. World Journal of Urology, 2022, 40, 385-390.	2.2	8
398	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. Hypertension, 2022, 79, 1257-1264.	2.7	8
399	No effect of ethanol ingestion on betaâ€adrenoceptorâ€mediated circulatory responses to isoprenaline in man British Journal of Clinical Pharmacology, 1985, 20, 684-687.	2.4	7
400	COMPARISON OF NORADRENALINE AND ISOPRENALINE REMOVAL IN THE CANINE HINDLIMB AND KIDNEY. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 777-781.	1.9	7
401	The influence of aging on the plasma concentration and renal clearance of homovanillic acid. Psychoneuroendocrinology, 1994, 19, 33-41.	2.7	7
402	Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma. Molecular and Cellular Endocrinology, 2011, 335, 69-77.	3.2	7
403	Genetics and the Clinical Approach to Paragangliomas. Hormone and Metabolic Research, 2014, 46, 964-973.	1.5	7
404	Volumetric Modeling of Adrenal Gland Size in Primary Bilateral Macronodular Adrenocortical Hyperplasia. Journal of the Endocrine Society, 2021, 5, bvaa162.	0.2	7
405	Left Ventricular Norepinephrine and Epinephrine Kinetics at Birth in Lambs. Circulation Research, 1997, 81, 438-447.	4.5	7
406	Angpt2/Tie2 autostimulatory loop controls tumorigenesis. EMBO Molecular Medicine, 2022, 14, e14364.	6.9	7
407	No improvement in ethanol-induced memory deficits after administration of a vasopressin analog. Life Sciences, 1985, 37, 2499-2505.	4.3	6
408	Gene Expression Profiling of Rat Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 290-299.	3.8	6
409	Cure of Neuroendocrine Carcinoma by Peptide Receptor Radionuclide Therapy. Clinical Nuclear Medicine, 2008, 33, 690-691.	1.3	6
410	Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?. Endocrine, 2011, 40, 75-79.	2.3	6
411	Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background. Cancers, 2019, 11, 743.	3.7	6
412	Functional significance of germline EPAS1 variants. Endocrine-Related Cancer, 2021, 28, 97-109.	3.1	6
413	Pheochromocytoma: Rediscovery as a Catecholamine-Metabolizing Tumor. Endocrine Pathology, 2003, 14, 193-212.	9.0	6
414	Strain-specific metastatic phenotypes in pheochromocytoma allograft mice. Endocrine-Related Cancer, 2018, 25, 993-1004.	3.1	6

#	Article	IF	Citations
415	Integration of artificial intelligence and plasma steroidomics with laboratory information management systems: application to primary aldosteronism. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1929-1937.	2.3	6
416	Concentrations of noradrenaline at neuronal uptakes sites during sympathetic nervous inhibition and activation in rabbits. Neurochemistry International, 1993, 22, 493-499.	3.8	5
417	In vivo kinetics of catecholamines. Autonomic and Autacoid Pharmacology, 1994, 14, 7-8.	0.6	5
418	Clues to the Diagnosis of Pheochromocytoma from the Differential Tissue Metabolism of Catecholamines. Advances in Pharmacology, 1997, 42, 374-377.	2.0	5
419	Sympathetic Carondioneuropathy in Dysautonomias. Advances in Pharmacology, 1997, 42, 615-619.	2.0	5
420	Adrenergic and Noradrenergic Plasma Levels in Lesch-Nyhan Disease. Neuropsychopharmacology, 2000, 22, 320-326.	5.4	5
421	Pheochromocytoma: recent advances and speed bumps in the road to further progress. Journal of Hypertension, 2006, 24, 2341-2343.	0.5	5
422	Metabolomic distinction of microvascular effects of lipoprotein apheresis– A pilot study. Atherosclerosis Supplements, 2013, 14, 143-149.	1.2	5
423	Adrenal Vein Catecholamine Levels and Ratios: Reference Intervals Derived from Patients with Primary Aldosteronism. Hormone and Metabolic Research, 2017, 49, 418-423.	1.5	5
424	The Adrenal Gland: Central Relay in Health and Disease. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 81-83.	1.2	5
425	Effect of Dietary Sodium Modulation on Pig Adrenal Steroidogenesis and Transcriptome Profiles. Hypertension, 2020, 76, 1769-1777.	2.7	5
426	Scoping review of COVID-19-related systematic reviews and meta-analyses: can we really have confidence in their results?. Postgraduate Medical Journal, 2022, 98, 372-379.	1.8	5
427	Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion. Discover Oncology, 2021, 12, 9.	2.1	5
428	Optimized procedures for testing plasma metanephrines in patients on hemodialysis. Scientific Reports, 2021, 11, 14706.	3.3	5
429	Simultaneous Liquid-Chromatographic Determination of Plasma Catecholamines and Metabolites. Clinical Chemistry, 2009, 55, 2223-2224.	3.2	4
430	Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. Analytical and Bioanalytical Chemistry, 2013, 405, 1713-1719.	3.7	4
431	Maternal and fetal factors which influence cord blood glucose levels in term infants delivered by cesarean section. Journal of Perinatal Medicine, 2015, 43, 339-346.	1.4	4
432	The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice. Hormone and Metabolic Research, 2017, 49, 466-471.	1.5	4

#	Article	IF	Citations
433	A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 2019, 188, 38-47.	2.5	4
434	Differential Responses of Urinary Epinephrine and Norepinephrine to 24-h Shift-Work Stressor in Physicians. Frontiers in Endocrinology, 2020, 11, 572461.	3.5	4
435	Catecholamines and Serotonin., 2012,, 851-894.		4
436	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3689-e3698.	3.6	4
437	Simultaneous development of pheochromocytomas in prepubertal siblings with von Hippel-Lindau syndrome. Journal of Pediatrics, 2002, 140, 625-628.	1.8	3
438	Genetic markers for the diagnosis and prognosis of pheochromocytoma. Expert Review of Endocrinology and Metabolism, 2009, 4, 45-52.	2.4	3
439	Pheochromocytoma or MÃ $\frac{1}{4}$ nchausen syndrome: the masquerade is up. Clinical Autonomic Research, 2010, 20, 211-212.	2.5	3
440	Commentary. Clinical Chemistry, 2013, 59, 1565-1566.	3.2	3
441	Arterio-venous differences in cord levels of catecholamines, glucose, lactate and blood gases. Journal of Perinatal Medicine, 2016, 44, 695-704.	1.4	3
442	Impact of Aldosterone Synthase Inhibitor FAD286 on Steroid Hormone Profile in Human Adrenocortical Cells. Hormone and Metabolic Research, 2017, 49, 701-706.	1.5	3
443	Catecholamines., 2018, , 21-24.		3
444	A pedunculated aldosteroneâ€producing adenoma drained by an extra vein causing puzzling results of adrenal vein sampling. Clinical Endocrinology, 2018, 89, 242-244.	2.4	3
445	Development of a Function-Integrative Sleeve for Medical Applications. Sensors, 2019, 19, 2588.	3.8	3
446	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. Journal of Hypertension, 2020, 38, 1551-1558.	0.5	3
447	Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma. Endocrine, 2022, 75, 254-265.	2.3	3
448	Pheochromocytoma and Paraganglioma., 2019,, 523-531.		3
449	Blood pressure profile, sympathetic nervous system activity and subclinical target organ damage in patients with polycythemia vera. Polish Archives of Internal Medicine, 2020, 130, 607-614.	0.4	3
450	Pheochromocytoma Concealed By Chronic Methamphetamine Abuse. AACE Clinical Case Reports, 2020, 6, e212-e216.	1.1	3

#	Article	IF	Citations
451	Ethanol-induced inhibition of the drinking response to hypertonic saline in the rat. Pharmacology Biochemistry and Behavior, 1985, 22, 493-496.	2.9	2
452	Plasma Metanephrines in the Diagnosis of Pheochromocytoma. Annals of Internal Medicine, 1996, 124, 695.	3.9	2
453	Seasonal variations of plasma normetaneprine levels: the authors reply. European Journal of Endocrinology, 2014, 170, L3.	3.7	2
454	Resection of Pheochromocytoma in a Patient Requiring Coronary Artery Bypass Grafting: First Things First. AACE Clinical Case Reports, 2016, 2, e25-e29.	1.1	2
455	Compensation for chronic oxidative stress in ALADIN null mice. Biology Open, 2018, 7, .	1.2	2
456	Steroid Profiling as an Additional Tool to Confirm One-Sided Hormone Overproduction in Primary Aldosteronism: A Case Report. Frontiers in Endocrinology, 2019, 10, 597.	3.5	2
457	Current Trends in Genetics of Pheochromocytoma. , 0, , 30-40.		2
458	Catecholamines and Adrenergic Receptors., 0,, 41-71.		2
459	Current Trends in Biochemical Diagnosis of Pheochromocytoma. , 0, , 72-92.		2
460	Aldo-Keto Reductases in Norepinephrine Metabolism. Advances in Experimental Medicine and Biology, 1999, 463, 459-463.	1.6	2
461	Somatic RET mutation in a patient with pigmented adrenal pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 150117.	0.5	2
462	Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model. Cells, 2022, 11, 560.	4.1	2
463	31 ACTIVE SURVEILLANCE OF PHEO IN VON HIPPEL-LINDAU (VHL) PATIENTS: EVALUATION OF SAFETY AND GROWTH RATES. Journal of Urology, 2010, 183, .	0.4	1
464	Dopaminergic Neurotransmission. , 2012, , 63-65.		1
465	Normetanephrine and Metanephrine. , 2017, , 420-424.		1
466	OC-0152: Glutamine metabolism as potential biomarker and target for prostate cancer radiosensitization. Radiotherapy and Oncology, 2018, 127, S76-S77.	0.6	1
467	New Way Forward for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Tumors with an LC-MS/MS Panel of Indole Biomarkers. Clinical Chemistry, 2019, 65, 1346-1347.	3.2	1
468	Commentary on Cryptogenic Cushing Syndrome Due to a White Lie. Clinical Chemistry, 2020, 66, 661-662.	3.2	1

#	Article	IF	CITATIONS
469	Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension. Clinical Autonomic Research, 2021, 31, 351-353.	2.5	1
470	Current Trends in Localization of Pheochromocytoma., 0,, 93-108.		1
471	Impact of Dietary Sodium Reduction on the Development of Obesity and Type 2 Diabetes in db/db Mice. Hormone and Metabolic Research, 2021, 53, 699-704.	1.5	1
472	The Adrenal Medulla., 2002, , 183-222.		1
473	Targeted Quantification of Carbon Metabolites Identifies Metabolic Progression Markers and an Undiagnosed Case of SDH-Deficient Clear Cell Renal Cell Carcinoma in a German Cohort. Metabolites, 2021, 11, 764.	2.9	1
474	Clinical Presentation of Pheochromocytoma., 0,, 8-29.		1
475	Increased voluntary ethanol intake after dietary salt-loading in rats. Pharmacology Biochemistry and Behavior, 1986, 24, 1825-1827.	2.9	0
476	Inhibition of uptake-1 activity in the human heart in a hypernoradrenergic state. Clinical Pharmacology and Therapeutics, 2004, 75, P54.	4.7	0
477	High-Throughput Molecular and Histopathologic Profiling of the Tumor Microenvironment in A Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. Journal of Immunotherapy, 2005, 28, 638-639.	2.4	0
478	Treatment of Pheochromocytoma., 0,, 109-113.		0
479	Labordiagnostik Katecholamin-produzierender Tumoren. Laboratoriums Medizin, 2013, 37, 187-197.	0.6	0
480	Impact of mineralocorticoid receptor blockade on vascular function in atherosclerotic mouse models under high-fat diet. Atherosclerosis, 2014, 235, e152-e153.	0.8	0
481	Tumor Metabolism and Metabolomics of Pheochromocytomas and Paragangliomas. , 2017, , 239-250.		0
482	SUN-222 Pre- and Post-Pubertal Reference Ranges for Oxygenated Androgens in Saliva. Journal of the Endocrine Society, 2020, 4, .	0.2	0
483	Intrarenal hemodynamics and kidney function in pheochromocytoma and paraganglioma before and after surgical treatment. Blood Pressure, 2021, 30, 1-8.	1.5	0
484	Normetanephrine and Metanephrine. , 2004, , 387-390.		0
485	Sympathoadrenal function in patients with paroxysmal hypertension. FASEB Journal, 2006, 20, A1184.	0.5	0
486	PhÃ ĕ chromozytom – Paragangliom. , 2010, , 270-277.		0

#	Article	lF	CITATIONS
487	Abstract LB-308: Effects of the IDH1 R132H mutation on redox status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation. , 2016, , .		0
488	Abstract 3391: Next generation sequencing paves the way for personalized medicine in pheochromocytoma and paraganglioma patients and their families. , 2017, , .		0
489	Paroxysmal Hypertension: Pheochromocytoma. Updates in Hypertension and Cardiovascular Protection, 2018, , 541-560.	0.1	O
490	OR02-6 Mass Spectrometry-Based Steroid Profiling Inprimary Bilateral Macronodular Adrenocortical Hyperplasia. Journal of the Endocrine Society, 2019, 3, .	0.2	0
491	Blood sampling for metanephrines: to stick or stick and wait?. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1609-1610.	2.3	O
492	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. Journal of the Endocrine Society, 2020, 4, .	0.2	0
493	Future Trends and Perspectives. , 0, , 114-119.		O
494	Abstract 543: Impact of Eplerenone on Vascular Function in LOX-1 Overexpressing Mice on High-Fat Diet. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	O